Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROFIT-CKD: Pemafibrate for renoprotective effect in CKD with hypertriglyceridemia
jRCT1071240094Completed
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in chronic kidney disease (CKD), hypertriglyceridemia and proteinuria (2 arms). Primary endpoint: Change of urinary protein amount at 12 months. Started Nov 2020; status: completed.
02
Drugs
pemafibrate
03
Conditions
chronic kidney disease (CKD)hypertriglyceridemiaproteinuria
Beyond the preview
Go deeper on jRCT1071240094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071240094.